The improvement of NASH symptoms by sweroside was accompanied with its inhibitory effects on the hepatic NLRP3 inflammasome as hepatic IL-1β and caspase-1 were decreased. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.